CSIMarket
 


Pds Biotechnology Corp  (PDSB)
Other Ticker:  
 

Pds Biotechnology's Leverage Ratio

PDSB's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 4.45%, Leverage Ratio fell to 1.34, a new company high.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 275 other companies have achieved lower Leverage Ratio than Pds Biotechnology in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 1577 to 1723 .

Explain Leverage Ratio?
Who are PDSB Customers?
What are PDSB´s Total Liabilities?


PDSB Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -47.97 % -36.91 % -26.6 % -30.39 % -30.65 %
Y / Y Total Liabilities Change 17.52 % 638.35 % 482.89 % 843.81 % 725.89 %
Leverage Ratio MRQ 1.34 0.97 0.67 0.75 0.59
PDSB's Total Ranking # 1723 # 1577 # 1331 # 1328 # 1295
Seq. Equity Change -24.54 % -20.89 % -6.8 % -6.5 % -8.49 %
Seq. Total Liabilities Change 4.45 % 14.11 % -16.87 % 18.61 % 556.23 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 276
Healthcare Sector # 559
Overall Market # 1723


Leverage Ratio Statistics
High Average Low
1.34 0.34 0.05
(Sep 30 2023)  




Financial Statements
Pds Biotechnology's Equity $ 24 Millions Visit PDSB's Balance sheet
Pds Biotechnology's Total Liabilities $ 33 Millions Visit PDSB's Balance sheet
Source of PDSB's Sales Visit PDSB's Sales by Geography


Cumulative Pds Biotechnology's Leverage Ratio

PDSB's Leverage Ratio for the trailling 12 Months

PDSB Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -47.97 % -36.91 % -26.6 % -30.39 % -30.65 %
Y / Y Total Liabilities TTM Growth 17.52 % 638.35 % 482.89 % 843.81 % 725.89 %
Leverage Ratio TTM 0.88 0.73 0.5 0.35 0.19
Total Ranking TTM # 1560 # 1419 # 1137 # 993 # 552
Seq. Equity TTM Growth -24.54 % -20.89 % -6.8 % -6.5 % -8.49 %
Seq. Total Liabilities TTM Growth 4.45 % 14.11 % -16.87 % 18.61 % 556.23 %


On the trailing twelve months basis Due to the net new borrowings of 4.45% during the trailing twelve months finishing in the III Quarter 2023, cumulativeLeverage Ratio improved to 0.88, a new company high.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry PDSB recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 103 to 2094.

Explain Leverage Ratio?
Who are PDSB Customers?
What are PDSB´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 1723


trailing twelve months Leverage Ratio Statistics
High Average Low
0.88 0.3 0.07
(Sep 30 2023)   (Mar 31 2022)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Aytu Biopharma Inc   3.13 $ 100.721  Millions$ 32.167  Millions
Sarepta Therapeutics Inc   3.04 $ 2,322.856  Millions$ 764.357  Millions
Eli Lilly And Company  2.94 $ 33,266.700  Millions$ 11,307.400  Millions
Harrow Inc   2.79 $ 210.308  Millions$ 75.402  Millions
Kineta Inc   2.77 $ 7.991  Millions$ 2.889  Millions
Marinus Pharmaceuticals Inc   2.65 $ 144.368  Millions$ 54.537  Millions
Journey Medical Corporation  2.62 $ 45.447  Millions$ 17.374  Millions
Durect Corp  2.55 $ 36.752  Millions$ 14.406  Millions
Apellis Pharmaceuticals Inc   2.52 $ 585.945  Millions$ 232.271  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Gossamer Bio Inc   2.33 $ 243.308  Millions$ 104.617  Millions
Phibro Animal Health Corporation  2.27 $ 620.465  Millions$ 273.069  Millions
Uniqure N v   2.21 $ 594.878  Millions$ 268.784  Millions
Biovie Inc   2.15 $ 16.212  Millions$ 7.548  Millions
Bristol myers Squibb Company  2.14 $ 62,265.000  Millions$ 29,062.000  Millions
G1 Therapeutics Inc   2.09 $ 90.075  Millions$ 43.022  Millions
Milestone Pharmaceuticals inc   2.06 $ 58.612  Millions$ 28.504  Millions
Cerevel Therapeutics Holdings Inc   2.01 $ 549.000  Millions$ 272.962  Millions
Abeona Therapeutics Inc   2.00 $ 44.049  Millions$ 22.038  Millions
Travere Therapeutics Inc   1.98 $ 553.084  Millions$ 279.766  Millions
Maravai Lifesciences Holdings Inc   1.96 $ 1,748.259  Millions$ 892.281  Millions
Jazz Pharmaceuticals Plc  1.92 $ 6,684.082  Millions$ 3,489.373  Millions
Cyclacel Pharmaceuticals Inc   1.91 $ 8.200  Millions$ 4.297  Millions
Syros Pharmaceuticals Inc   1.87 $ 67.800  Millions$ 36.302  Millions
Ibio inc   1.85 $ 24.469  Millions$ 13.209  Millions
Veru Inc   1.85 $ 32.813  Millions$ 17.783  Millions
Catalyst Biosciences Inc   1.83 $ 6.447  Millions$ 3.517  Millions
Clene Inc   1.82 $ 39.027  Millions$ 21.406  Millions
Zoetis Inc   1.78 $ 9,028.000  Millions$ 5,074.000  Millions
Nektar Therapeutics  1.77 $ 282.876  Millions$ 159.368  Millions

Date modified: 2023-11-16T17:21:31+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com